Small caps round-up: DQ Entertainment, Tristel, ReNeuron
DQ Entertainment, a producer of animation, visual effects, game art and live action entertainment content for the global media and entertainment industry, has won three new contracts for co-production. The first is with French broadcaster TF1 for the new 3D animated TV series of Robin Hood, the second is with Minika ATV for its new kids network in Turkey and the third is with Gaurmont Alphanim for the new 3D animated CGI TV series "Lanfeust".
DQ Entertainment, a producer of animation, visual effects, game art and live action entertainment content for the global media and entertainment industry, has won three new contracts for co-production. The first is with French broadcaster TF1 for the new 3D animated TV series of Robin Hood, the second is with Minika ATV for its new kids network in Turkey and the third is with Gaurmont Alphanim for the new 3D animated CGI TV series "Lanfeust".
Tristel, a manufacturer of infection control, contamination control and hygiene products, has terminated its supply arrangement with Medichem International for disinfectants and cleaning products. Tristel will now directly market these products to veterinary practices, hospitals under Tristel related brands. Tristel is now free to address the veterinary market directly and to broaden its product offering within areas that it had not been directly involved with, including its core hospital marketplace.
ReNeuron Group, a UK-based stem cell company, has announced a firm placing to raise up to £9.4m before expenses with the shares being sold at 4p each. The issue price represents a discount of around 21.2% to the mid-market closing price of 5.075p on the day before the placing was announced. In addition, investors in the placing are being issued warrants to subscribe for ordinary shares, which could raise up to another £8.1m for the company, before expenses, if the warrants are exercised. The company also said that to date no adverse reactions had been seen in the five stroke patients who have been administered with its ReN001 stem cell therapy treatment. The company expects to be able to apply for a phase II study next year.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
NR
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.
-
Reducing cash ISA limit will make lending difficult and expensive, warn providers
An open letter from the Building Societies Association has urged the chancellor to keep the cash ISA limit at £20,000. We look at whether a smaller cash ISA allowance will make it harder to get a mortgage or loan
-
Nvidia becomes world's first $4 trillion company
The AI boom has catapulted Nvidia’s share price to astronomic heights, becoming the world’s most valuable company and the first to pass the $4 trillion milestone